Analyst Price Target Update on Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) should head towards $55.5 per share according to 2 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $53 per share. The higher price estimate target is at $58 according to the Analysts.

Many analysts have stated their opinion on the company shares. Barclays upgrades its view on Sanofi (NYSE:SNY) according to the research report released by the firm to its investors. The shares have now been rated Overweight by the stock experts at the ratings house. Earlier, the shares had a rating of Equal-weight. The rating by the firm was issued on May 12, 2016. For the current week, the company shares have a recommendation consensus of Buy.

Sanofi (NYSE:SNY) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.41 points or 1.04% at $39 with 1,743,665 shares getting traded. Post opening the session at $39.21, the shares hit an intraday low of $39 and an intraday high of $39.56 and the price was in this range throughout the day. The company has a market cap of $101,844 million and the number of outstanding shares have been calculated to be 2,611,393,500 shares. The 52-week high of Sanofi (NYSE:SNY) is $54.98 and the 52-week low is $37.63.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.